Exome sequencing reveals mutant genes with low penetrance involved in MEN2A-associated tumorigenesis

Endocrine-Related Cancer

Volumn 22, Issue 1, 2015, Pages 23-33

  Cai, Jie ^a   Li, Lin ^b   Ye, Lei ^a   Jiang, Xiaohua ^a   Shen, Liyun ^a   Gao, Zhibo ^b   Fang, Weiyuan ^a   Huang, Fengjiao ^a   Su, Tingwei ^a   Zhou, Yulin ^a   Wang, Weiqing ^a   Ning, Guang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BGI SHENZHEN   (China)

Author keywords

EIF4G1; Exome sequencing; MEN2A; RET

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN RET; DNA;

ADULT; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; COPY NUMBER VARIATION; EIF4G1 GENE; ENDOCRINE TUMOR; EXOME; FEMALE; GENE; GENE MUTATION; GENOME ANALYSIS; GERMLINE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTATIONAL ANALYSIS; NEURAL CREST; ONCOGENE RET; PENETRANCE; POINT MUTATION; PROTEIN PHOSPHORYLATION; SINGLE NUCLEOTIDE POLYMORPHISM; SIPPLE SYNDROME; SOMATIC MUTATION; THYROID MEDULLARY CARCINOMA; BLOOD; CELL GROWTH; GENETIC TRANSFECTION; GENETICS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; NUCLEOTIDE SEQUENCE; PATHOLOGY;

ADULT; CARCINOGENESIS; CELL GROWTH PROCESSES; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; EXOME; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PENETRANCE; POINT MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSFECTION;

EID: 84923546027     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0225     Document Type: Article

References (44)

1. Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts NJ, Bhan S, Ho AS, Khan Z, Bishop J et al. 2013 Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. Journal of Clinical Endocrinology and Metabolism 98 E364-E369. (doi:10.1210/jc.2012-2703)
2. Asai N, Iwashita T, Matsuyama M & Takahashi M 1995 Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Molecular and Cellular Biology 15 1613-1619.
3. Benn DE, Dwight T, Richardson AL, Delbridge L, Bambach CP, Stowasser M, Gordon RD, Marsh DJ & Robinson BG 2000 Sporadic and familial pheochromocytomas are associated with loss of at least two discrete intervals on chromosome 1p. Cancer Research 60 7048-7051.
4. Carlomagno F, Guida T, Anaganti S, Vecchio G, Fusco A, Ryan AJ, Billaud M & Santoro M 2004 Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 23 6056-6063. (doi:10.1038/sj.onc.1207810)
5. Chabre O, Piolat C & Dyon JF 2007 Childhood progression of hereditary medullary thyroid cancer. New England Journal of Medicine 356 1583-1584. (doi:10.1056/NEJMc076067)
6. Chau NG & Haddad RI 2013 Vandetanib for the treatment of medullary thyroid cancer. Clinical Cancer Research 19 524-529. (doi:10.1158/1078-0432.CCR-12-2353)
7. Ciampi R, Mian C, Fugazzola L, Cosci B, Romei C, Barollo S, Cirello V, Bottici V, Marconcini G, Rosa PM et al. 2013 Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid 23 50-57. (doi:10.1089/thy.2012.0207)
8. Cromer MK, Starker LF, Choi M, Udelsman R, Nelson-Williams C, Lifton RP & Carling T 2012 Identification of somatic mutations in parathyroid tumors using whole-exome sequencing. Journal of Clinical Endocrinology and Metabolism 97 E1774-E1781. (doi:10.1210/jc.2012-1743)
9. Dar AC, Das TK, Shokat KM & Cagan RL 2012 Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature 486 80-84. (doi:10.1038/nature11127)
10. Diaz-Cano SJ, de Miguel M, Blanes A, Tashjian R & Wolfe HJ 2001 Germline RET 634 mutation positive MEN-2A related C-cell hyperplasias have genetic features consistent with intraepithelial neoplasia. Journal of Clinical Endocrinology and Metabolism 86 3948-3957. (doi:10.1210/jcem.86.8.7739)
11. Feng GS, Ouyang YB, Hu DP, Shi ZQ, Gentz R & Ni J 1996 Grap is a novel SH3-SH2-SH3 adaptor protein that couples tyrosine kinases to the Ras pathway. Journal of Biological Chemistry 271 12129-12132. (doi:10.1074/jbc.271.21.12129)
12. Flicker K, Ulz P, Höger H, Zeitlhofer P, Haas OA, Behmel A, Buchinger W, Scheuba C, Niederle B, Pfragner R & Speicher MR 2012 High resolution analysis of alterations in medullary thyroid carcinoma genomes. International Journal of Cancer 131 E66-E73. (doi:10.1002/ijc.26494)
13. Huang SC, Koch CA, Vortmeyer AO, Pack SD, Lichtenauer UD, Mannan P, Lubensky IA, Chrousos GP, Gagel RF, Pacak K et al. 2000 Duplication of the mutant RET allele in trisomy 10 or loss of the wild-type allele inmmultiple endocrine neoplasia type 2-associated pheochromocytomas. Cancer Research 60 6223-6226.
14. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A et al. 2008 Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321 1801-1806. (doi:10.1126/science.1164368)
15. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M et al. 2009 Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19 565-612. (doi:10.1089/thy.2008.0403)
16. Koch CA, Huang SC, Zhuang Z, Stolle C, Azumi N, Chrousos GP, Vortmeyer AO & Pacak K 2002 Somatic VHL gene deletion and point mutation in MEN-2A-associated pheochromocytoma. Oncogene 21 479-482. (doi:10.1038/sj.onc.1205133)
17. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F et al. 2011 Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. Journal of Clinical Oncology 29 2660-2666. (doi:10.1200/JCO.2010.32.4145)
18. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA et al. 2013 Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499 214-218. (doi:10.1038/nature12213)
19. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES & Getz G 2014 Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505 495-501. (doi:10.1038/nature12912)
20. Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD, Wahl RA, Lamesch P, Raue F, Conte-Devolx B et al. 2003 Early malignant progression of hereditary medullary thyroid cancer. New England Journal of Medicine 349 1517-1525. (doi:10.1056/NEJMoa012915)
21. Macià A, Gallel P, Vaquero M, Gou-Fabregas M, Santacana M, Maliszewska A, Robledo M, Gardiner JR, Basson MA, Matias-Guiu X et al. 2012 Sprouty1 is a candidate tumor-suppressor gene in medullary thyroid carcinoma. Oncogene 31 3961-3972. (doi:10.1038/onc.2011.556)
22. Michiels FM, Chappuis S, Caillou B, Pasini A, Talbot M, Monier R, Lenoir GM, Feunteun J & Billaud M 1997 Development of medullary thyroid carcinoma in transgenic mice expressing the RET proto-oncogene altered by a multiple endocrine neoplasia type 2A mutation. PNAS 94 3330-3335. (doi:10.1073/pnas.94.7.3330)
23. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L et al. 1993 Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363 458-460. (doi:10.1038/363458a0)
24. Newey PJ, Nesbit MA, Rimmer AJ, Attar M, Head RT, Christie PT, Gorvin CM, Stechman M, Gregory L, Mihai R et al. 2012 Whole-exome sequencing studies of nonhereditary (sporadic) parathyroid adenomas. Journal of Clinical Endocrinology and Metabolism 97 E1995-E2005. (doi:10.1210/jc.2012-2303)
25. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL et al. 2008 An integrated genomic analysis of human glioblastoma multiforme. Science 321 1807-1812. (doi:10.1126/science.1164382)
26. Patel MR, Sadiq AA, Jay-Dixon J, Jirakulaporn T, Jacobson BA, Farassati F, Bitterman PB & Kratzke RA 2012 Novel role of c-jun N-terminal kinase in regulating the initiation of cap-dependent translation. International Journal of Oncology 40 577-582. (doi:10.3892/ijo.2011.1252)
27. Ramírez-Valle F, Braunstein S, Zavadil J, Formenti SC & Schneider RJ 2008 eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy. Journal of Cell Biology 181 293-307. (doi:10.1083/jcb.200710215)
28. Rosai J, Carcangiu ML & DeLellis RA. 1992 Tumors of the thyroid gland. In Atlas of Tumor Pathology pp 207-240. eds J Rosai & LH Sobin Washington, DC: Armed Forces Institute of Pathology.
29. Ruiz LS, Montero-Conde C, Milne RL, Moya CM, Cebrián A, Letón R, Cascón A, Mercadillo F, Landa I, Borrego S et al. 2007 Association study of 69 genes in the ret pathway identifies low-penetrance loci in sporadic medullary thyroid carcinoma. Cancer Research 67 9561-9567. (doi:10.1158/0008-5472.CAN-07-1638)
30. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Vecchio G, Matoskova B, Kraus MH et al. 1995 Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267 381-383. (doi:10.1126/science.7824936)
31. Schlee S, Carmillo P & Whitty A 2006 Quantitative analysis of the activation mechanism of the multicomponent growth-factor receptor Ret. Nature Chemical Biology 2 636-644. (doi:10.1038/nchembio823)
32. Silvera D, Arju R, Darvishian F, Levine PH, Zolfaghari L, Goldberg J, Hochman T, Formenti SC & Schneider RJ 2009 Essential role for eIF4GI overexpression in the pathogenesis pathogenesis of inflammatory breast cancer. Nature Cell Biology 11 903-908. (doi:10.1038/ncb1900)
33. Sipple JH 1961 Association of pheochromocytoma with carcinoma of thyroid gland. American Journal of Medicine 31 163-166. (doi:10.1016/0002-9343(61)90234-0)
34. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S et al. 2006 The consensus coding sequences of human breast and colorectal cancers. Science 314 268-274. (doi:10.1126/science.1133427)
35. Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK & Wells SA Jr 2005 Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. New England Journal of Medicine 353 1105-1113. (doi:10.1056/NEJMoa043999)
36. Solomon B & Rischin D 2012 Progress in molecular targeted therapy for thyroid cancer: vandetanib in medullary thyroid cancer. Journal of Clinical Oncology 30 119-121. (doi:10.1200/JCO.2011.37.8638)
37. Takahashi C, Contreras B, Iwanaga T, Takegami Y, Bakker A, Bronson RT, Noda M, Loda M, Hunt JL & Ewen ME 2006 Nras loss induces metastatic conversion of Rb1-deficient neuroendocrine thyroid tumor. Nature Genetics 38 118-123. (doi:10.1038/ng1703)
38. Tu L, Liu Z, He X, He Y, Yang H, Jiang Q, Xie S, Xiao G, Li X, Yao K et al. 2010 Over-expression of eukaryotic translation initiation factor 4 gamma1 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma. Molecular Cancer 9 78-88. (doi:10.1186/1476-4598-9-78)
39. Van Veelen W, Van Gasteren CJ, Acton DS, Franklin DS, Berger R, Lips CJ & Höppener JW 2008 Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development. Cancer Research 68 1329-1337. (doi:10.1158/0008-5472.CAN-07-5754)
40. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR et al. 2011 Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer:a randomized, double-blind phase III trial. Journal of Clinical Oncology 29 134-141. (doi:10.1200/JCO.2010.30.1655)
41. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J et al. 2007 The genomic landscapes of human breast and colorectal cancers. Science 318 1108-1113. (doi:10.1126/science.1145720)
42. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA et al. 2010 Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467 1114-1117. (doi:10.1038/nature09515)
43. Ye L, Santarpia L, Cote GJ, El-Naggar AK & Gagel RF 2008 High resolution array-comparative genomic hybridization profiling reveals deoxyribo-nucleic acid copy number alterations associated with medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 93 4367-4372. (doi:10.1210/jc.2008-0912)
44. Zhou Y, Zhao Y, Cui B, Gu L, Zhu S, Li J, Liu J, Yin M, Zhao T, Yin Z et al. 2007 RET proto-oncogene mutations are restricted to codons 634 and 918 in mainland Chinese families with MEN2A and MEN2B. Clinical Endocrinology 67 570-576. (doi:10.1111/j.1365-2265.2007.02927.x)